CN106215095A - The Chinese medicine preparation for the treatment of blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia - Google Patents
The Chinese medicine preparation for the treatment of blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia Download PDFInfo
- Publication number
- CN106215095A CN106215095A CN201610652572.7A CN201610652572A CN106215095A CN 106215095 A CN106215095 A CN 106215095A CN 201610652572 A CN201610652572 A CN 201610652572A CN 106215095 A CN106215095 A CN 106215095A
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- chinese medicine
- blood stasis
- medicine preparation
- prostatic hyperplasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 104
- 210000004369 blood Anatomy 0.000 title claims abstract description 100
- 239000003814 drug Substances 0.000 title claims abstract description 96
- 230000007812 deficiency Effects 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 35
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 35
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 37
- 210000000582 semen Anatomy 0.000 claims abstract description 21
- 241000237903 Hirudo Species 0.000 claims abstract description 20
- 241000005787 Cistanche Species 0.000 claims abstract description 16
- 241000756943 Codonopsis Species 0.000 claims abstract description 14
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 14
- 241000628997 Flos Species 0.000 claims abstract description 13
- 241001250596 Pleione Species 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 2
- 244000178320 Vaccaria pyramidata Species 0.000 claims 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 abstract description 36
- 230000001737 promoting effect Effects 0.000 abstract description 20
- 208000024891 symptom Diseases 0.000 abstract description 16
- 230000017531 blood circulation Effects 0.000 abstract description 11
- 230000004087 circulation Effects 0.000 abstract description 8
- 208000037920 primary disease Diseases 0.000 abstract description 8
- 229940126532 prescription medicine Drugs 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 42
- 210000002307 prostate Anatomy 0.000 description 30
- 210000000952 spleen Anatomy 0.000 description 26
- 210000004185 liver Anatomy 0.000 description 24
- 241000700159 Rattus Species 0.000 description 23
- 208000002193 Pain Diseases 0.000 description 15
- 230000036407 pain Effects 0.000 description 15
- 210000001015 abdomen Anatomy 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000027939 micturition Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 9
- 108010051457 Acid Phosphatase Proteins 0.000 description 9
- 102000013563 Acid Phosphatase Human genes 0.000 description 9
- 201000000736 Amenorrhea Diseases 0.000 description 8
- 206010001928 Amenorrhoea Diseases 0.000 description 8
- 231100000540 amenorrhea Toxicity 0.000 description 8
- 210000004907 gland Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 206010000087 Abdominal pain upper Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 230000000762 glandular Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229960001712 testosterone propionate Drugs 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 5
- 206010020853 Hypertonic bladder Diseases 0.000 description 5
- 208000019790 abdominal distention Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 201000001881 impotence Diseases 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 208000009205 Tinnitus Diseases 0.000 description 4
- 208000031975 Yang Deficiency Diseases 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 231100000886 tinnitus Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 239000003390 Chinese drug Substances 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100001252 long-term toxicity Toxicity 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 230000003202 urodynamic effect Effects 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 210000005124 simple cuboidal epithelium Anatomy 0.000 description 2
- 210000005123 simple squamous epithelium Anatomy 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 201000002327 urinary tract obstruction Diseases 0.000 description 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 241000336316 Cistanche tubulosa Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014328 Ejaculation failure Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010038490 Renal pain Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- ZXKXJHAOUFHNAS-UHFFFAOYSA-N fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+]C(C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000004441 taeniasis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/10—Peat; Amber; Turf; Humus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of Chinese medicine preparation treating blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia, its crude drug comprises Herba Leonuri, Fructus Psoraleae, Hirudo, Rhizoma Sparganii, Rhizoma Curcumae, Radix Salviae Miltiorrhizae, Flos Carthami, Caulis Spatholobi, Radix et Rhizoma Rhei (stir-fried with wine), Rhizoma Cyperi (processed), Semen Pharbitidis, Herba Lysimachiae, succinum, Pseudobulbus Cremastrae Seu Pleiones, Rhizoma dioscoreae, Radix Codonopsis, Poria, Fructus Corni, Semen Cuscutae, Fructus Lycii and Herba Cistanches.Chinese medicine preparation of the present invention carries out prescription medicine treatment, invigorating kidney, promoting blood circulation, blood stasis dispelling circulation of qi promoting for the prostatic hyperplasia of blood stasis due to renal deficiency pattern of syndrome, improve rapidly prostatic hyperplasia symptom, effectively reduce operation utilization rate, improve patient compliance, provide a kind of effective treatment means for final treatment primary disease.
Description
Technical field
The present invention relates to technical field of Chinese medicine, particularly relate to a kind of Chinese medicine treating blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia
Preparation.
Background technology
Prostatic hyperplasia (BPH) is one of middle-aging male common disease, cumulative many with population in the world senescence onset of illness.
The sickness rate of prostatic hyperplasia was incremented by with the age, but not necessarily had clinical symptoms when having preneoplastic lesions.Cities and towns sickness rate is higher than township
Village, and race difference also affects hyperplasia degree.
The early stage of prostatic hyperplasia due to compensatory, atypical symptom, along with lower urinary tract obstruction increases the weight of, symptom is gradually obvious,
Clinical symptoms includes urine storage phase symptom, urinate phase symptom and post micturition symptoms.Owing to course advancement is slow, it is difficult to determine onset
Time.
The hazardness of prostatic hyperplasia is produced pathophysiological change after being to cause lower urinary tract obstruction.Its pathology is individual
Diversity is very big, nor all develops in Progressive symmetric erythrokeratodermia.A part of pathological changes is to the most not developing deeply, even if so occurring
Slight obstruction is the most not both needed to operation.
Slight to symptom, IPSS marks less than 7 points observables, it is not necessary to treatment, is scored above 7 then need for IPSS
Carry out Drug therapy.The medicine that key agents treatment uses has: (1) 5α-reductase inhibitor.Research finds that 5α-reductase is
The important enzyme that testosterone changes to dihydrotestosterone.Dihydrotestosterone has certain effect in prostatic hyperplasia, therefore uses 5 α-reduction
Enzyme inhibitor can give certain suppression to hypertrophy；(2) alpha-blocking agent is it is now recognized that this type of medicine can improve urinary tract
Dynamic property is blocked, and makes drop in resistance to improve symptom, and common medicine has hytrin etc.；(3) the most widely used person of antiandrogen is pregnant
Ketone medicine；(4) other include m receptor antagonist, galenical, Chinese medicine etc..It addition, doctor trained in Western medicine is main for the treatment of primary disease
By operative treatment, but operative treatment wound is relatively big, and patient compliance is poor, another it has been reported that, by operation on prostate,
Perineal nerves therefrom some our Peripheral nerve damage that not yet anatomical isolation goes out can be caused, cause irreversible anejaculation,
Therefore, there is greater risk for male patient in operation on prostate.
The traditional Chinese medical science has it for the understanding of primary disease from ancient times, is classified as essence gallery, the difficulty in urination, stranguria etc., enters its etiology and pathogenesis
Row is analyzed, predominantly syndrome of qi deficiency of lung and kidney, syndrome of yang deficiency of spleen and kidney, blood stasis due to renal deficiency card etc., and Chinese medicine preparation of the present invention is demonstrate,proved for blood stasis due to renal deficiency
The prostatic hyperplasia of type carries out prescription medicine treatment, invigorating kidney, promoting blood circulation, blood stasis dispelling circulation of qi promoting, improves rapidly prostatic hyperplasia symptom, effectively
Reduce operation utilization rate, improve patient compliance, provide a kind of effective treatment means for final treatment primary disease.
Summary of the invention
The technical problem to be solved is to provide a kind of for treating in blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia
Medicine preparation, the traditional Chinese medical science has it for the understanding of primary disease from ancient times, is classified as essence gallery, the difficulty in urination, stranguria etc., carries out its etiology and pathogenesis
Analyzing, predominantly syndrome of qi deficiency of lung and kidney, syndrome of yang deficiency of spleen and kidney, blood stasis due to renal deficiency card etc., Chinese medicine preparation of the present invention is for blood stasis due to renal deficiency pattern of syndrome
Prostatic hyperplasia carry out prescription medicine treatment, invigorating kidney, promoting blood circulation, blood stasis dispelling circulation of qi promoting, improve rapidly prostatic hyperplasia symptom, effectively subtract
Perform the operation less utilization rate, improve patient compliance, provide a kind of effective treatment means for final treatment primary disease.
For solving above-mentioned technical problem, the present invention provides a kind of Chinese medicine system treating blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia
Agent, its crude drug includes Herba Leonuri, Fructus Psoraleae, Hirudo, Rhizoma Sparganii, Rhizoma Curcumae, Radix Salviae Miltiorrhizae, Flos Carthami, Caulis Spatholobi, Radix et Rhizoma Rhei (stir-fried with wine), Rhizoma Cyperi (processed), leads
Fructus Arctii, Herba Lysimachiae, succinum, Pseudobulbus Cremastrae Seu Pleiones, Rhizoma dioscoreae, Radix Codonopsis, Poria, Fructus Corni, Semen Cuscutae, Fructus Lycii and Herba Cistanches.
Wherein, Herba Leonuri in described Chinese medicine preparation: Fructus Psoraleae: the weight ratio of Hirudo is 2: 3: 1.
Wherein, in described Chinese medicine preparation, the weight of Hirudo is less than 10g.
Wherein, in described Chinese medicine preparation the quality of each crude drug be specifically as follows Herba Leonuri 10g～20g, Fructus Psoraleae 15g～
30g, Hirudo 5g～10g, Rhizoma Sparganii 6g～8g, Rhizoma Curcumae 10g～12g, Radix Salviae Miltiorrhizae 15g～30g, Flos Carthami 8g～10g, Caulis Spatholobi 13g～
15g, Radix et Rhizoma Rhei (stir-fried with wine) 8g～15g, Rhizoma Cyperi (processed) 9g～15g, Semen Pharbitidis 3g～5g, Herba Lysimachiae 6g～10g, succinum 3g～5g, Pseudobulbus Cremastrae Seu Pleiones
9g～11g, Rhizoma dioscoreae 20g～30g, Radix Codonopsis 19g～21g, Poria 15g～30g, Fructus Corni 9g～11g, Semen Cuscutae 20g～
30g, Fructus Lycii 14g～16g, Herba Cistanches 15g～21g.
Wherein, in described Chinese medicine preparation, the quality of each crude drug is specifically as follows Herba Leonuri 10g, Fructus Psoraleae 15g, Hirudo
5g, Rhizoma Sparganii 7g, Rhizoma Curcumae 11g, Radix Salviae Miltiorrhizae 11g, Flos Carthami 9g, Caulis Spatholobi 14g, Radix et Rhizoma Rhei (stir-fried with wine) 9g, Rhizoma Cyperi (processed) 10g, Semen Pharbitidis 4g, Herba Lysimachiae
7g, succinum 4g, Pseudobulbus Cremastrae Seu Pleiones 10g, Rhizoma dioscoreae 14g, Radix Codonopsis 20g, Poria 20g, Fructus Corni 10g, Semen Cuscutae 10g, Fructus Lycii 15g,
Herba Cistanches 15g.
Present invention also offers the preparation method of above-mentioned Chinese medicine preparation, particularly as follows:
Capture ingredients by weight, put in decoction medicinal cupping, add the soak by water of 5 times of each quality of medicinal material sums, first
Intense fire boils, slow fire boiling subsequently 3 hours, and decoction liquor filters, and medicinal residues add the water of homogenous quantities again, and after same first intense fire, slow fire is decocted
Boiling, decoct 3 hours, decoction liquor filters, and twice decoction liquor merges, and is condensed into the decoction medicinal liquid of 0.5g/ml～1g/ml.
Useful technique effect
Chinese medicine preparation of the present invention carries out prescription medicine treatment for the prostatic hyperplasia of blood stasis due to renal deficiency pattern of syndrome, invigorating kidney, promoting blood circulation,
Blood stasis dispelling circulation of qi promoting, improves rapidly prostatic hyperplasia symptom, effectively reduces operation utilization rate, improves patient compliance, for finally controlling
Treat primary disease and a kind of effective treatment means is provided.
Detailed description of the invention
For the prostatic hyperplasia of patient's blood stasis due to renal deficiency pattern of syndrome, its kidney asthenia as the principal aspect, blood stasis is mark, has the deficiency of vital energy concurrently, because of patient
For middle-aged and elderly people, its deficiency of kidney-QI, stagnation of QI-blood, long-term working principle, even excess of sexual intercourse, causes blood stasis in lower energizer to add in addition
Weight, sending out is the difficulty in urination, and treatment is this when the kidney invigorating righting, and blood circulation promoting and blood stasis dispelling, for marking, is held concurrently with regulating QI to relieve pain, inducing diuresis to remove edema.
Based on above-mentioned Therapeutic Principle, the present invention proposes a kind of Chinese medicine preparation treating blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia,
Its crude drug includes Herba Leonuri, Fructus Psoraleae, Hirudo, Rhizoma Sparganii, Rhizoma Curcumae, Radix Salviae Miltiorrhizae, Flos Carthami, Caulis Spatholobi, Radix et Rhizoma Rhei (stir-fried with wine), Rhizoma Cyperi (processed), leads a cow
Son, Herba Lysimachiae, succinum, Pseudobulbus Cremastrae Seu Pleiones, Rhizoma dioscoreae, Radix Codonopsis, Poria, Fructus Corni, Semen Cuscutae, Fructus Lycii and Herba Cistanches.
Chinese medicine preparation of the present invention, under this method for the treatment of instructs, uses Chinese prescription compatibility, is now presented below with regard to its prescription thinking:
Chinese medicine preparation of the present invention is with Herba Leonuri, Fructus Psoraleae, Hirudo for monarch drug group, and Herba Leonuri specially enters blood system, kind invigorating blood circulation
The stasis of blood, regulating menstruation diuretic, has clots absorbing blood and fresh blood is not hindered, and supports fresh blood and the most stagnant effect of blood stasis, and scalable smooth muscle contraction function is right
In blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia there is good therapeutical effect, and Fructus Psoraleae have a kidney invigorating and YANG supporting, warming spleen and stopping diarrha effect,
It is mainly used in decline of the fire from the gate of life, the performance of a series of diseases such as below element deficiency and cold, insufficiency of kidney-YANG, part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels deficiency and coldness, it is impossible to resolving fluid-retention with drugs of warm nature, cold coagulation
Blood stasis increases the weight of the state of an illness further, and Hirudo is Drug Prepared from Insects, and property is walked to alter, and removing blood stasis dynamics is relatively strong, has the most broken for blood stasis in lower energizer
Blood removing blood stasis effect, but this medicine by wound is just crossed, and will strictly control dosage, therefore find through clinical research, for blood of suffering from a deficiency of the kidney
The Patients with Prostatic Hyperplasia of blood stasis syndrome type, Herba Leonuri: Fructus Psoraleae: Hirudo ratio is 2: 3: 1 preferably, and with Herba Leonuri for monarch drug group in
Core drug, the consumption of single pair of Chinese traditional medicine leech may not exceed 10g, and under this dosage, patient can improve rapidly difficulty in urination symptom, with
Time reduce complication occur, be finally reached minimizing operation utilization rate, increase patients ' life quality purpose.The traditional Chinese medical science is cured the disease and is particular about reason
Method side's medicine, Chinese medicine use the compatibility application being particular about monarch, Chinese medicine preparation of the present invention uses Rhizoma Sparganii, Rhizoma Curcumae, Radix Salviae Miltiorrhizae, red
The medicines such as flower, Caulis Spatholobi, succinum, Radix et Rhizoma Rhei (stir-fried with wine), coordinate monarch drug Herba Leonuri, Hirudo blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, wherein Rhizoma Sparganii, Rhizoma Curcumae
The removing blood stasis power that disappears is strong, and Radix Salviae Miltiorrhizae, Flos Carthami coordinate, clearing away heat and cooling blood, and Caulis Spatholobi priming enters blood, also have preferable clearing away heat and cooling blood merit simultaneously
Effect, succinum has the hemostasis of good dissipating blood stasis；Relieving stranguria by diuresis effect, can coordinate the medicine mind tranquilizing and the heart calming such as Poria simultaneously, and Radix Et Rhizoma Rhei passes through
Concocting, its diarrhea dynamics weakens, and lower blood stasis effect strengthens, and Yin Qishang has and rushes down lower effect, can give evil with outlet, use system perfume
Attached vital energy regualting and blood circulation-promoting pain relieving, the pain for causing because of the difficulty in urination has good therapeutical effect；Chinese medicine preparation of the present invention uses Rhizomadioscoreae
Medicine, Fructus Corni, Semen Cuscutae, Fructus Lycii and Herba Cistanches Chinese medicine of the five flavours coordinate monarch drug Fructus Psoraleae liver and kidney tonifying, warming and recuperating the kidney-YANG, Qi Zhonghuai
Rhizoma Dioscoreae tonifying liver spleen kidney, it is possible to nourishing kidney yin, is simultaneously introduced in the medicine of kidney-replenishing, has kind YANG invigorating person, as the meaning for the treatment of YANG within YIN, mountain Zhu
Cornel, Semen Cuscutae, Fructus Lycii warming and recuperating the kidney-YANG, Herba Cistanches kidney-replenishing but the driest strong, all medicines share, and are ministerial drug group altogether；Chinese medicine of the present invention
Preparation adds a small amount of Radix Codonopsis, Poria and Rhizoma dioscoreae, and spleen invigorating helps fortune, temper to fill strong, then transporting degree of having, and the defeated cloth of qi-blood-body fluid is just
Often, three burnt mechanisms of qi are unobstructed, then water liquid is walked from urine, and all medicines share, for adjuvant drug；Because of its blood stasis due to renal deficiency, cause the difficulty in urination obstructed, this
Bright Chinese medicine preparation adds a small amount of Semen Pharbitidis, Herba Lysimachiae plays inducing diuresis for treating stranguria syndrome effect, additionally, the generation of primary disease has local inflammation more,
Pseudobulbus Cremastrae Seu Pleiones coordinates two medicines to have good heat-clearing and toxic substances removing, anti-inflammation detumescence effect, and all medicines share, for making medicine.All formulas are matched, and the kidney invigorating is lived
Blood, blood stasis dispelling circulation of qi promoting, there is good curative effect for blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia.
Described list pay the quality of each crude drug in Chinese medicine be specifically as follows Herba Leonuri 10g～20g, Fructus Psoraleae 15g～30g,
Hirudo 5g～10g, Rhizoma Sparganii 6g～8g, Rhizoma Curcumae 10g～12g, Radix Salviae Miltiorrhizae 15g～30g, Flos Carthami 8g～10g, Caulis Spatholobi 13g～15g,
Radix et Rhizoma Rhei (stir-fried with wine) 8g～15g, Rhizoma Cyperi (processed) 9g～15g, Semen Pharbitidis 3g～5g, Herba Lysimachiae 6g～10g, succinum 3g～5g, Pseudobulbus Cremastrae Seu Pleiones 9g～
11g, Rhizoma dioscoreae 20g～30g, Radix Codonopsis 19g～21g, Poria 15g～30g, Fructus Corni 9g～11g, Semen Cuscutae 20g～30g, Chinese holly
Fructus Lycii 14g～16g, Herba Cistanches 15g～21g.
Described list is paid the quality of each crude drug in Chinese medicine and is specifically as follows Herba Leonuri 10g, Fructus Psoraleae 15g, Hirudo 5g, Rhizoma Sparganii
7g, Rhizoma Curcumae 11g, Radix Salviae Miltiorrhizae 11g, Flos Carthami 9g, Caulis Spatholobi 14g, Radix et Rhizoma Rhei (stir-fried with wine) 9g, Rhizoma Cyperi (processed) 10g, Semen Pharbitidis 4g, Herba Lysimachiae 7g, succinum
4g, Pseudobulbus Cremastrae Seu Pleiones 10g, Rhizoma dioscoreae 14g, Radix Codonopsis 20g, Poria 20g, Fructus Corni 10g, Semen Cuscutae 10g, Fructus Lycii 15g, Herba Cistanches
15g。
Each crude drug pharmacology is as follows:
Herba Leonuri: nature and flavor are pungent, bitter, cool, GUIXIN bag, Liver Channel.Specially enter blood system, kind blood circulation promoting and blood stasis dispelling, regulating menstruation diuretic, have clots absorbing
Blood and fresh blood is not hindered, support fresh blood and the most stagnant effect of blood stasis, scalable smooth muscle contraction function, for blood stasis due to renal deficiency pattern of syndrome prostatitis
Gland hypertrophy has good therapeutical effect.
Fructus Psoraleae: acrid in the mouth, hardship, warm in nature, enter kidney, spleen channel, have kidney invigorating and YANG supporting, warming spleen and stopping diarrha effect, be mainly used in the gate of vitality
Fire declines, the chills and pain of the waist and kness of below element deficiency and cold, frequent urination and enuresis, sexual impotence lingering diarrhea；Insufficiency of kidney-YANG, spleen soil lose using warming therapy stomachache limb and tremble with fear, diarrhea before dawn
The card such as rush down.
Hirudo: taste becomes, hardship, property is put down, is entered Liver Channel, have effect of removing blood stasis, for blood stasis amenorrhea, lump in the abdomen stomachache, storage
The cards such as blood, traumatic blood stasis are had a pain, carbuncle erysipelas.
Rhizoma Sparganii: bitter in the mouth, pungent, property puts down, enters liver, spleen channel, has a removing blood stasis circulation of qi promoting, effect of removing food stagnancy pain relieving, for blood stasis amenorrhea,
Dysmenorrhea, puerperal the stagnant stomachache of the stasis of blood, lump in the abdomen mass in the abdomen in abdomen, stagnation of QI due to dyspepsia, the card such as abdominal distention.
Rhizoma Curcumae: acrid in the mouth, hardship, warm in nature, enter liver, spleen channel, there is removing blood stasis circulation of qi promoting, effect of removing food stagnancy pain relieving, for qi depression to blood stasis
Caused lump in the abdomen mass in the abdomen, chest and abdomen stasis of blood pain, amenorrhea, dysmenorrhea, abdominal distention, traumatic injury, blood stasis swells and ache to wait and demonstrate,proves.
Radix Salviae Miltiorrhizae: bitter in the mouth, cold in nature, enters the heart, Liver Channel, has blood circulation promoting and blood stasis dispelling, promoting tissue regeneration by removing blood stasis, the effect of removing heat from blood mind calming, be mainly used in
The ambition of stagnation of QI and blood, breast side of body twinge, sensation of oppression over the chest with shortness of breath, abdominal distention；The menoxenia of women's disharmony between QI and blood, dysmenorrhoea amenorrhea；The QI and blood stasis of blood
Stagnant, trusted subordinate's pain etc. is demonstrate,proved.
Flos Carthami: warm in nature, acrid in the mouth, enter, the heart, Liver Channel, there is promoting blood circulation to restore menstrual flow, the effect of stasis-dispelling and pain-killing, for amenorrhea, dysmenorrhea,
Lochia, lump in the abdomen mass in the abdomen, injury from falling down, skin infection such as swells and ache at the card.
Caulis Spatholobi: latin name spatholobicaulis, bitter in the mouth, sweet, warm in nature, return liver, kidney channel, have expansion blood vessel, enrich blood
Invigorate blood circulation, regulating menstruation, the effect of relaxing muscles and tendons and activating QI and blood in the collateral, platelet aggregation is had obvious inhibitory action, promotes animal kidney and uterus total phosphorus
Metabolism, curing mainly treatment blood deficiency has the menoxenia of silt, and limbs pain is meciless, and soreness of the waist and knees, pain etc. are demonstrate,proved.
Radix et Rhizoma Rhei (stir-fried with wine): latin name RheiRadixetRhizoma, bitter in the mouth, cold in nature, return stomach warp；Large intestine channel；Liver Channel；Spleen channel, tool
Attack stagnant；Clearing away damp-heat；Pathogenic fire purging；Removing heat from blood；Blood stasis dispelling；Effect of removing toxic substances, cures mainly excess-heat constipation；The accumulation of heat feeling of stuffiness in chest；Damp-heat dysentery；Yellow
Subcutaneous ulcer；Gonorrhea；Edema abdominal distention；Dysuria；Conjunctival congestion；Laryngopharynx swelling and pain；Aphtha of the mouth and tongue；Gastropyretic vomiting；Spit blood；Spitting of blood；Epistaxis；Just
Blood；Hematuria；Blood-retention；Amenorrhea；Puerperal the stagnant stomachache of the stasis of blood；Lump in the abdomen；Traumatic injury；Pyretic toxicity carbuncle and ulcer；Erysipelas；The cards such as scald.
Rhizoma Cyperi (processed): acrid in the mouth, hardship sweet, micro-, property is flat, returns liver, tri-jiao channel, has resolving depression of regulating the flow of vital energy, and effect of menstruction regulating and pain relieving cures mainly
Stagnation of QI due to depression of the liver, breast, the side of body, abdominal distention, dyspepsia, menoxenia, amenorrhea dysmenorrhea, colic of cold type stomachache, distending pain of the breast etc. is demonstrate,proved.
Semen Pharbitidis: cold in nature, bitter in the mouth, poisonous, removing water retention by purgation relieving constipation, expectorant washs drink, and parasite killing is attacked long-pending.For edema distension, two are not the most
Logical, phlegm retention is gathered, and QI rising in reverse order is breathed with cough, abdominal pain due to worm stagnation, ascarid, taeniasis.
Herba Lysimachiae: sweet in the mouth, slightly stringy pulse, cold nature, enters liver, gallbladder, kidney, bladder warp, has clearing away heat-damp and promoting diuresis, Tonglin Paishi, removing toxic substances
Effect of detumescence, cures mainly liver and gall and urinary system calculus；Pyretic stranguria；Oedema due to nephritis；Jaundice due to damp-heat；Sore carbuncle；Venom；Traumatic injury
The cards such as damage.
Succinum: sweet in the mouth, property are flat；GUIXIN, liver, small intestinal, bladder, lung, spleen channel.Tranquillizing the mind by relieving convulsion；Dissipating blood stasis stops blooding；Relieving stranguria by diuresis；
Removing nebula improving eyesight.Main palpitation with fear insomnia；Infantile convulsion epilepsy；Stranguria with blood hematuria；Amenorrhea due to stagnation of blood；Puerperal the stagnant stomachache of the stasis of blood；Lump in the abdomen；The raw barrier of mesh
Nebula；Carbuncle sore tumefacting virus.
Pseudobulbus Cremastrae Seu Pleiones: sweet in the mouth, micro-pungent, cool in nature, to return liver, spleen channel, there is heat-clearing and toxic substances removing, effect of dissipating phlegm and resolving masses, for carbuncle
Furunculosis, scrofula sucutaneous nodule, tuberculous lymphadenitis, snake bite and insect sting etc. is demonstrate,proved.
Rhizoma dioscoreae: latin name dioscoreaerhizoma, sweet in the mouth, property are flat, enter lung, spleen, stomach warp, have spleen reinforcing nourishing the stomach, lung benefiting
Reinforce the kidney, the effect of YIN nourishing and the production of body fluid promoting, cure mainly weakness of the spleen and stomach, the lack of appetite poor appetite of dysfunction of the spleen in transportation, the vexed diarrhoea of gastral cavity etc. is demonstrate,proved.
Radix Codonopsis: sweet in the mouth, property put down, enter lung, spleen channel, have QI invigorating strengthening the spleen, the effect of nourishing blood to promote the production of body fluid, be mainly used in deficiency of both the splenic and pulmonary QI or
The fatigue and weakness of QI and blood deficiency, breathing hard, the symptom such as cough spontaneous perspiration, Radix Codonopsis is longer than spleen reinforcing nourishing the stomach, adjusts regulating the function of middle-JIAO, has the work nourished blood concurrently
Put down by, its property, spleen invigorating fortune and the driest；Flavour is cloudy and the wettest, it is possible to improves the immune state of body, improves resistance against diseases, promotes
Digest and assimilate, improve metabolism, promote the intestinal absorption to nutrient substance.
Poria: sweet in the mouth, light, property is put down, is entered spleen, lung, bladder, heart channel, have eliminating dampness and diuresis, the effect of spleen invigorating mind calming, mainly use
In the edema of retention of water-damp, dysuria；The pyretic stranguria of damp-heat accumulation, the stagnation of the anorexia and loose stool of stagnation of dampness due to deficiency of the spleen, phlegm retention, epilepsy etc.
Card.
Fructus Corni: latin name cornifructus, sour in the mouth, puckery, slightly warm in nature, return liver, kidney channel, there is liver and kidney tonifying, arresting seminal emission
Gu de-effect.For vertigo and tinnitus, soreness of waist and knee joint, impotence and seminal emission, enuresis frequent micturition, bleeding not during menses, profuse sweating is collapsed.Interior-heat is quenched one's thirst
Deng card.
Semen Cuscutae: sweet in the mouth, pungent, property puts down, enters liver,kidney,spleen warp, have the kidney invigorating and essence nourishing, the effect of nourishing the liver to improve visual acuity, is mainly used in kidney
The sexual impotence of YANG deficiency, premature ejaculation of passing out semen, frequent micturition, dizziness and tinnitus；Suffering from a deficiency of the kidney pain in the lumbar region, married woman's leukorrhagia, nausea is solid；Both liver and kidney deficiency,
The binocular of deficiency of liver-blood is dim-sighted, blurring of vision；The loose stool stomachache of asthenia of both the spleen and kidney, aqueous-grainy diarrhea etc. is demonstrate,proved.
Fructus Lycii: latin name lyciifructus, sweet in the mouth, property are flat, enter liver, kidney channel, have liver and kidney tonifying, nourish blood enrich blood, benefit
Shrewd head, the effect of nourishing the lung to arrest cough, be mainly used in liver and kidney deficiency, the soreness of the waist and knees of asthenia of essence and blood, dizziness and tinnitus, seminal emission tinnitus,
Unconsciously sweat and tire；The sexual impotence of insufficiency of kidney-YANG, sterile；Deficiency of YIN-essence, deficiency of liver-blood eyes is dim-sighted and the card such as deficiency of YIN chronic cough.
Herba Cistanches: for Orobanchaceae Cistanche Hoffmgg. et Link plants Herba Cistanches and the fleshy stem of Cistanche Tubulosa, latin name
Herbacistanches, sweet in the mouth, one-tenth, warm in nature, enter kidney, large intestine channel, have kidney-replenishing, benefiting essence-blood, the effect of loosening bowel to relieve constipation, it is used for
Kidney yang deficiency, the impotence and premature ejaculation of asthenia of essence and blood, sterility and infertility, soreness of waist and knee joint, Hiccough and deaf, frequent micturition urine number, suffer from a deficiency of the kidney dryness of the intestine and product
The constipation of rear blood deficiency, after being ill deficiency of body fluid etc. are demonstrate,proved.
Present invention also offers the preparation method of above-mentioned Chinese medicine preparation, particularly as follows:
Capture ingredients by weight, put in decoction medicinal cupping, add the soak by water of 5 times of each quality of medicinal material sums, first
Intense fire boils, slow fire boiling subsequently 3 hours, and decoction liquor filters, and medicinal residues add the water of homogenous quantities again, and after same first intense fire, slow fire is decocted
Boiling, decoct 3 hours, decoction liquor filters, and twice decoction liquor merges, and is condensed into the decoction medicinal liquid of 0.5g/ml～1g/ml.
Embodiment is below used to describe embodiments of the present invention in detail, whereby to the present invention how application technology means
Solve technical problem, and the process that realizes reaching technique effect can fully understand and implement according to this.
Embodiment 1 decoction liquor 1
Capture Herba Leonuri 10g, Fructus Psoraleae 15g, Hirudo 5g, Rhizoma Sparganii 7g, Rhizoma Curcumae 11g, Radix Salviae Miltiorrhizae 11g, Flos Carthami 9g, Caulis Spatholobi
14g, Radix et Rhizoma Rhei (stir-fried with wine) 9g, Rhizoma Cyperi (processed) 10g, Semen Pharbitidis 4g, Herba Lysimachiae 7g, succinum 4g, Pseudobulbus Cremastrae Seu Pleiones 10g, Rhizoma dioscoreae 14g, Radix Codonopsis 20g,
Poria 20g, Fructus Corni 10g, Semen Cuscutae 10g, Fructus Lycii 15g, Herba Cistanches 15g, put in decoction medicinal cupping, add the water of 1.2kg
Decocting, first intense fire boils, slow fire boiling subsequently 3 hours, and decoction liquor filters, the water of medicinal residues 1.2kg again, and same first intense fire is hereinafter
Fire decocts, and decocts 3 hours, and decoction liquor filters, and twice decoction liquor merges, and is condensed into the decoction medicinal liquid of 0.5g/ml～1g/ml.
Comparable group
Using Herba Leonuri weight is 5g to use the preparation method identical with the embodiment of the present invention 1, difference to be in crude drug,
Obtain decoction liquor 2.
Chinese medicine toxicological experiment of the present invention
Patient suffers from prostatic hyperplasia, according to its treatment the course for the treatment of be more than 2 months, therefore treatment need long-term prescription, in order to
Verifying the safety of Chinese medicine preparation long-term taking of the present invention, spy carries out Chinese medicine preparation long term toxicity of the present invention research.
Long term toxicity test
Cleaning grade KM mice, 40, male and female half and half, freely ingest, take the photograph water.
Use the embodiment of the present invention 1 preparation decoction liquor 1000ml, obtain after pressurized filtration containing crude drug concentration be
The filtrate 50ml of 17.26g/ml, 4 DEG C of preservations, standby, it is heated to 36～39 DEG C during use.
According to table of random number, mice is divided into matched group and experimental group, and (gastric infusion invention formulation decoction liquor filters
Liquid 17.2/ml, is equivalent to crude drug amount 51.6g/kg/d).Gastric infusion amount is 0.1ml/10g body weight, matched group gavage distilled water
0.1ml/10g body weight.3 times/day, successive administration 60 days, drug withdrawal is observed 14 days.Record Mouse Weight, take food, drinking-water situation, note
The every reaction of mice after record gastric infusion, the every physiological reaction of phase mice between gastric infusion, and death condition.
By long_term toxcity experimentation, observing situation after 60d mouse stomach is administered, before gastric infusion is administered, each group is dynamic
Object weighs, takes food, situation of drinking water no difference of science of statistics, after gastric infusion is administered, and each group Mouse Weight change, feed drinking-water feelings
Condition, no difference of science of statistics., there is not death and other toxic reactions in behavioristics's Non Apparent Abnormality.
This experimental group dosage (crude drug concentration 51.6g/kg/d), mice is 10.01 with the dosage conversion coefficient of adult,
Therefore mice dosage is 134.74 times of clinical adult's medication (adult male 60kg, i.e. 3.83g/kg/d), through continuously
The administration of 60 days, is administered mice and occurs without overt toxicity response situation, and drug withdrawal is observed 14 days, also shows without cumulative toxicity, therefore
It is considered that this medicine is safe.Being verified by this long term toxicity test, this medicine successive administration, without notable toxic reaction, can be recognized
Fixed, the medication of this clinical drug is safe.
Clinical research
Physical data
In October, 2015～in April, 2016, at outpatient service and inpatient, wherein 103 examples meet blood stasis due to renal deficiency pattern of syndrome
Prostatic hyperplasia male patient, by fully ensuring that patient rights and interests, on the basis of informed consent, selects to use operative treatment patient
It is 53 examples, No operation patient 50 example.Severity Scaling standard is with reference to " andrology's disease that calls for specialized treatment tcm clinical practice diagnosis and treatment " standard.53 example No operation are suffered from
Person's age 50～73 years old, average 52.5 ± 5.6 years old, course of disease March～12 years, average out to 4.0 ± 2.1 years.50 example postoperative patient years
Age 51～77 years old, average 53.6 ± 6.0 years old, course of disease April～10 years, average out to 5.2 ± 2.1 years.Each controlled observation group the age,
The aspect no significant differences (P ＞ 0.05) such as the course of disease and state of an illness weight, have comparability.
Diagnostic criteria and inclusion criteria
The diagnostic criteria of BPH, according to " andrology's disease that calls for specialized treatment tcm clinical practice diagnosis and treatment ", refers to inspection mainly by age, medical history, symptom, anus
And ultrasonic examination and uroflometry and make a definite diagnosis.Inclusion criteria: urinating by the world and control association (ICS) definition, the urine storage phase forces urine
Flesh pressure amplitude ＞ 15cmH2O is judged as USB, selected research case.
Get rid of type
Get rid of outside nervous system disease, endocrinopathy history, vesical calculus, tumor of prostate, psychotic, lower urinary tract
Hinder history, more than 3 months persons of operation on prostate, fail to treat person's full course for the treatment of.
Standards of Chinese Medical Syndrome Differentiation
According to " Diagnostics of Chinese Medicine " CM syndrome differentiation criterion, two groups of patients belong to blood stasis due to renal deficiency.
Therapeutic Method
No operation Chinese drug-treated group
Giving and the decocting for Chinese herbal medicine liquid 1 of the embodiment of the present invention 1 preparation, be decocted in water for oral dose, every day 1 dose, every dose of 80ml, 15 days is 1 treatment
Journey, repeats urodynamics test after 4 courses for the treatment of of taking medicine.Acute urinary retention, row catheter urethral catheterization such as occur during treatment.
Operation group
Verification treatment is carried out, in my institute's row Treatment of Benign Prostatic Hyperplasia operation, art according to prostatic hyperplasia clinical therapeutic guideline
Rear infection etc..
Observation index
Steady to severity Scaling and detrusor before and after treatment according to " andrology's disease that calls for specialized treatment tcm clinical practice diagnosis and treatment " severity Scaling method
The urodynamics index such as qualitative is observed.
Steady to severity Scaling and detrusor before and after treatment according to " andrology's disease that calls for specialized treatment tcm clinical practice diagnosis and treatment " severity Scaling method
The urodynamics index such as qualitative is observed.
Outcome measure
Criterion of therapeutical effect is judged: clinical cure: normal according to " severity Scaling "；Effective: severity Scaling reduces by 2 grades；Have
Effect: severity Scaling reduces by 1 grade；Invalid: severity Scaling is unchanged or grade raises.
Criterion of therapeutical effect is judged: detrusor instability (di) is reduced to " effectively " according to " detrusor instability (di) rate " situation；Detrusor
Unstable without being reduced to engineering noise.
Statistical analysis
Using statistical analysis software SPSS16.0, data carry out t inspection, ranked data use rank test.
Result
Detrusor instability (di) rate before and after Chinese drug-treated group and treatment of control group, severity Scaling be relatively shown in Table 1, table 2.
Before and after treatment respectively organized by table 1, detrusor instability (di) rate situation compares
Note: the comparison before and after group internal therapy,*P ＜ 0.01；Compare the same period with operative control group,△P ＜ 0.05
The comparative example of therapeutic effect respectively organized by table 2
| Group | Clinical cure | Effective | Effectively | Invalid | Total effective rate % |
| No operation Chinese drug-treated group | 21 | 19 | 7 | 3 | 94.00* |
| Postoperative matched group | 11 | 13 | 18 | 11 | 79.25 |
Note: after treatment, compares with operative control group,*P ＜ 0.05
The result of Tables 1 and 2, it can be seen that No operation group patient, uses Chinese medicine expectant treatment, can effectively drop after taking medicine
The aspects such as low patient's detrusor instability (di) rate, reduction state of an illness grade have significant curative effect, and are better than operative control group, and difference has significantly
Property (P ＜ 0.05).
By the comparison to two groups of patient's entirety curative effects, use the comprehensive treatment of the expectant treatment method of Chinese medicine preparation of the present invention
Effect is significantly better than the comprehensive therapeutic effect of postoperative patients, it can be considered that Chinese medicine preparation of the present invention has good therapeutical effect.
Experimentation
Laboratory animal: 40 bull Kunming rats, 2 months ages of Mus, body weight 160～180g.Rat is random by body weight
It is divided into 4 groups；Normal group, model group, invention group, comparable group.
Material and reagent
The decoction liquor 1 of the embodiment of the present invention 1 preparation and the decoction liquor 2 of comparative example 1 preparation, be condensed into 5g crude drug/mL respectively,
4 DEG C save backup.
Testosterone propionate injection, Jinan Luo Ke Trade Co., Ltd. provides, specification 25mg/mL.
Prostate acid phosphatase radioimmunoassay, test kit is that BPC company of the U.S. produces.
Packet is with administration: prepares with reference to rat model, takes Adult male rats 60, is randomly divided into 4 groups: normal control
Group, model group, invention group, comparable group.In addition to Normal group, remaining each group is done castration respectively Mus and performs the operation: rat penta bar
Ratio appropriate sodium (400mg/kg) intraperitoneal injection of anesthesia, through scrotum row aseptic operation, extracts bilateral testes.Beginning medication in postoperative 7 days: mould
Type group castrated rats subcutaneous injection testosterone propionate 4mL/kg, uses normal saline gavage, every day 2 times simultaneously；Invention group castration is big
Decoction liquor 1 gavage 5mL/kg that Mus is prepared by the embodiment of the present invention 1 while subcutaneous injection testosterone propionate, every day 2 times.Ratio
Decoction liquor 2 gavage 5mL/kg that relatively group castrated rats is prepared with comparative example 1 of the present invention while subcutaneous injection testosterone propionate,
Every day 2 times.Rats in normal control group subcutaneous injection refines Oleum Sesami, uses normal saline gavage, every day 2 times.The equal medication 5 of each group above
Week.
Draw materials and result detects: put to death rat with cervical dislocation after 5 weeks, open abdominal cavity immediately, peel off around prostate
Tissue, wins prostate, weighs and prostate weight in wet base, calculates prostate index (prostate weight in wet base (mg)/rat body weight
(g)).Taking out anterior lobe of prostate Bouins ' liquid-solid fixed, routine paraffin wax embeds, serial section, after HE dyeing, uses graphical analysis
Processing system observes rat prostate tissue structure.Take prostate head lobe and rear side leaf respectively, add 0.1mol/L phosphate and delay
Rush liquid (pH7.4), make 10% homogenate, with centrifuge, take supernatant and measure acid phosphatase (ACP), prostate-specific
Property acid phosphatase (PAP) and the content of total protein.The content of ACP and PAP represents with U/gprot.
Statistical procedures
Every reference withRepresent, use SPSS statistical package to calculate meansigma methods and the degree of scatter of each index.In groups
Designing multiple mean and compare employing ANOVA inspection, multiple sample averages ask that each two compares employing q inspection.
Result
Rat prostate weight and the change of prostate index, the results are shown in Table 3.
Table 3 present invention and the present invention go the Herba Leonuri impact on rat prostate ponderal index
| Group | n | Weight of prostate (mg) | Prostate index |
| Normal group | 15 | 411.82±33.84 | 2.19±0.19 |
| Model group | 15 | 447.20±45.61* | 2.18±0.48* |
| Of the present invention group | 15 | 345.78±41.26**Δ | 1.49±0.10**Δ |
| Comparable group | 15 | 368.38±45.52Δ | 1.77±0.41Δ# |
Note: compare with blank group,*P ＜ 0.05；**P ＜ 0.01；Compare with model group,ΔP ＜ 0.01；With of the present invention group of ratio
Relatively,#P ＜ 0.05.
As shown in table 3, decoction liquor 1 and decoction liquor 2 substantially reduce rat prostate weight and prostate index, show this
The benign prostatic hyperplasia that bright Chinese medicine preparation is caused after can substantially suppressing castrated rats injection testosterone propionate, but invention group swashs
Substantially (the former is P ＜ 0.01, the latter P ＜ than the effect of comparable group to send out the effect reducing rat prostate weight and prostate index
0.05), illustrate that Herba Leonuri consumption is too small, can reduce rat prostate weight and the effect of prostate index.
Rat prostate acid phosphatase and the change of prostate specific acid phosphatase activity level, the results are shown in Table 4.
The impact of table 4 rat prostate ACPPAP
| n | ACP | PAP | |
| Normal group | 15 | 5.22±0.19 | 2.13±0.20 |
| Model group | 15 | 8.03±1.17* | 4.99±0.44* |
| Of the present invention group | 15 | 5.01±1.13ΔΔ | 2.39±0.22ΔΔ |
| The present invention goes Herba Leonuri group | 15 | 5.43±1.22*Δ# | 3.71±0.31*Δ# |
Note: compare with blank group, * P ＜ 0.05；Compare with model group,ΔP ＜ 0.01；ΔΔP ＜ 0.01；With of the present invention group of ratio
Relatively,#P ＜ 0.05.
As shown in table 4, invention group and comparable group prostate ACP level are substantially less than model group (the former are P ＜ 0.01, the latter P
＜ 0.05), and of the present invention group of prostate ACP level is substantially less than comparable group, illustrates that Herba Leonuri plays in prescription absolute
Effect.
Impact pathological on rat prostate tissue
In the specimen of HE dyeing, Normal Adult Rat prostatic epithelium mostly is in simple cuboidal epithelium or false cladding column
Skin, has secretions to fill in alveolar lumen, glandular epithelium stretches into formation folds in a garment to cell, and body of gland asks that matter is evenly distributed.Rat is being plucked
Except a period of time after the testis of both sides, prostata tissue atrophy, glandular epithelium is thinning, minority degeneration of glandular cells edema, and cellular layer
Number reduces, and nipple reduces, and body of gland asks that matter significantly reduces.Prostata tissue glandular epithelium can be made after castrated rats testosterone propionate to become
Height, alveolar lumen has full thing, asks cell plastid hypertrophy, body of gland increasing number, and in cystic dilatation, the glandular epithelium number of plies increases, many
For simple cuboidal epithelium, there is nipple hypertrophy.
With rat prostate epithelial atrophy after gavage of the present invention, acinus surface pleat disappears, and lumen of gland is smooth, major part
Glandular epithelium mostly is simple squamous epithelium, and nucleus is little and justifies, and between two parties, body of gland asks that matter is few, is distributed sparse, and substrate smooth muscle is less.
With prostate epithelial cell cell after decoction liquor 2 gavage of comparable group, atrophy also occurring, acinus surface pleat is few, and lumen of gland is smooth,
Part glandular epithelium mostly is simple squamous epithelium, and nucleus is less, and body of gland asks that matter is few, is distributed sparse.
In sum, Chinese medicine preparation of the present invention target improvement each for prostatic hyperplasia rat has a remarkable effect, and wherein
Herba Leonuri plays decisive role.
All above-mentioned primary these intellectual properties of enforcement, do not set this new product of enforcement limiting other forms
And/or new method.Those skilled in the art will utilize this important information, and foregoing is revised, to realize similar execution feelings
Condition.But, all modifications or transformation belong to the right of reservation based on new product of the present invention.
The above, be only presently preferred embodiments of the present invention, is not the restriction that the present invention makees other form, appoints
What those skilled in the art changed possibly also with the technology contents of the disclosure above or be modified as equivalent variations etc.
Effect embodiment.But every without departing from technical solution of the present invention content, the technical spirit of the foundation present invention is to above example institute
Any simple modification, equivalent variations and the remodeling made, still falls within the protection domain of technical solution of the present invention.
Claims (6)
1. the Chinese medicine preparation treating blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia, it is characterised in that: crude drug includes Herba Leonuri, benefit
Bone fat, Hirudo, Rhizoma Sparganii, Rhizoma Curcumae, Radix Salviae Miltiorrhizae, Flos Carthami, Caulis Spatholobi, Radix et Rhizoma Rhei (stir-fried with wine), Rhizoma Cyperi (processed), Semen Pharbitidis, Herba Lysimachiae, succinum, Pseudobulbus Cremastrae Seu Pleiones,
Rhizoma dioscoreae, Radix Codonopsis, Poria, Fructus Corni, Semen Cuscutae, Fructus Lycii and Herba Cistanches.
2. the Chinese medicine preparation treating blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia as claimed in claim 1, it is characterised in that: in described
Herba Leonuri in medicine preparation: Fructus Psoraleae: the weight ratio of Hirudo is 2: 3: 1.
3. the Chinese medicine preparation treating blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia as claimed in claim 1 or 2, it is characterised in that: institute
State the weight of Hirudo in Chinese medicine preparation and be less than 10g.
4. the Chinese medicine preparation of the treatment blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia as described in claims 1 to 3, it is characterised in that: each
The quality of crude drug is specifically as follows Herba Leonuri 10g～20g, Fructus Psoraleae 15g～30g, Hirudo 5g～10g, Rhizoma Sparganii 6g～8g, cowherb
Art 10g～12g, Radix Salviae Miltiorrhizae 15g～30g, Flos Carthami 8g～10g, Caulis Spatholobi 13g～15g, Radix et Rhizoma Rhei (stir-fried with wine) 8g～15g, Rhizoma Cyperi (processed) 9g～
15g, Semen Pharbitidis 3g～5g, Herba Lysimachiae 6g～10g, succinum 3g～5g, Pseudobulbus Cremastrae Seu Pleiones 9g～11g, Rhizoma dioscoreae 20g～30g, Radix Codonopsis
19g～21g, Poria 15g～30g, Fructus Corni 9g～11g, Semen Cuscutae 20g～30g, Fructus Lycii 14g～16g, Herba Cistanches 15g～
21g。
5. the Chinese medicine preparation of the treatment blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia as described in Claims 1-4, it is characterised in that: each
The quality of crude drug is specifically as follows Herba Leonuri 10g, Fructus Psoraleae 15g, Hirudo 5g, Rhizoma Sparganii 7g, Rhizoma Curcumae 11g, Radix Salviae Miltiorrhizae 11g, Flos Carthami
9g, Caulis Spatholobi 14g, Radix et Rhizoma Rhei (stir-fried with wine) 9g, Rhizoma Cyperi (processed) 10g, Semen Pharbitidis 4g, Herba Lysimachiae 7g, succinum 4g, Pseudobulbus Cremastrae Seu Pleiones 10g, Rhizoma dioscoreae 14g,
Radix Codonopsis 20g, Poria 20g, Fructus Corni 10g, Semen Cuscutae 10g, Fructus Lycii 15g, Herba Cistanches 15g.
6. the preparation method of Chinese medicine preparation described in claim 1 to 5, it is characterised in that:
Capture ingredients by weight, put in decoction medicinal cupping, add the soak by water of 5 times of each quality of medicinal material sums, first intense fire
Boiling, slow fire boiling subsequently 3 hours, decoction liquor filters, and medicinal residues add the water of homogenous quantities again, slow fire boiling after same first intense fire,
Decocting 3 hours, decoction liquor filters, and twice decoction liquor merges, and is condensed into the decoction medicinal liquid of 0.5g/ml～1g/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610652572.7A CN106215095A (en) | 2016-08-11 | 2016-08-11 | The Chinese medicine preparation for the treatment of blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610652572.7A CN106215095A (en) | 2016-08-11 | 2016-08-11 | The Chinese medicine preparation for the treatment of blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106215095A true CN106215095A (en) | 2016-12-14 |
Family
ID=57548364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610652572.7A Pending CN106215095A (en) | 2016-08-11 | 2016-08-11 | The Chinese medicine preparation for the treatment of blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106215095A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107050391A (en) * | 2017-04-30 | 2017-08-18 | 徐士魁 | It is a kind of to treat medicine of hyperplasia of prostate and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104873854A (en) * | 2015-06-17 | 2015-09-02 | 宋友春 | Traditional Chinese medicine preparation for rteriolar nephrosclerosis and preparation method thereof |
-
2016
- 2016-08-11 CN CN201610652572.7A patent/CN106215095A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104873854A (en) * | 2015-06-17 | 2015-09-02 | 宋友春 | Traditional Chinese medicine preparation for rteriolar nephrosclerosis and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 侯思理；等: "益母草治疗前列腺增生症有良效", 《中国民族民间医药杂志》 * |
| 廖泽云；等: "补中益气汤和补阳还五汤对大鼠前列腺增生影响的实验研究", 《中医药学刊》 * |
| 黄震；等: "补肾活血散结汤治疗前列腺增生症36例", 《安徽中医学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107050391A (en) * | 2017-04-30 | 2017-08-18 | 徐士魁 | It is a kind of to treat medicine of hyperplasia of prostate and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103656535B (en) | A kind of Chinese medicine composition for the treatment of hyperlipemia and preparation method thereof | |
| CN104740222A (en) | Traditional Chinese medicine for treating leucoderma | |
| CN102600419B (en) | Chinese medicinal composition for treating chronic appendagitis, and preparation method thereof | |
| CN102526597A (en) | Medicament for treating ozostomia and preparation method thereof | |
| CN105596861A (en) | Pill used for treating adverse reaction after CT enhancement scanning and preparation method | |
| CN106215095A (en) | The Chinese medicine preparation for the treatment of blood stasis due to renal deficiency pattern of syndrome prostatic hyperplasia | |
| CN103735792B (en) | A kind of medicine for the treatment of menoxenia and preparation method thereof | |
| CN103110756B (en) | Traditional Chinese medicine composition for treating renal hematuria | |
| CN106177327A (en) | The Chinese medicine preparation for the treatment of insufficiency of QI of the lung and kidney pattern of syndrome prostatic hyperplasia | |
| CN104547872A (en) | Traditional Chinese medicine composition for treating epilepsy | |
| CN104771637A (en) | Cholagogic and lithagogue agent for treating gallstone and preparation method thereof | |
| CN103845547A (en) | Traditional Chinese medicine decoction for treating mumps | |
| CN103800822A (en) | Traditional Chinese medicinal composition for treating hypertensive cerebral hemorrhage | |
| CN103800561A (en) | Traditional Chinese medicine for treating renal hematuria | |
| CN108653681A (en) | A kind of drug and preparation method thereof for treating senile dementia | |
| CN103638463B (en) | Medicine for treating menopause and preparation method of medicine | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN102274472A (en) | Traditional Chinese medicine patch for treating female dysmenorrhoea and preparation thereof | |
| CN106075180A (en) | A kind of Chinese medicine treating intravertebral anesthesia postoperative urine retention and preparation method thereof | |
| CN106421694A (en) | Externally used Chinese herba preparation for treating dysmenorrhea | |
| CN105796676A (en) | Pills for effectively treating fatty liver | |
| CN105327295A (en) | Capsules for treating hepatitis and preparing method thereof | |
| CN105412825A (en) | Drug for treating hyperlipidaemia and preparation method thereof | |
| CN105288315A (en) | Christina loosestrife herb oral liquid for clearing away heat, removing dampness, benefiting bile and expelling toxin and preparation method of christina loosestrife herb oral liquid | |
| CN105497420A (en) | Medicine for treating primary osteoporosis through kidney-tonifying, spleen-strengthening and blood-stasis-removing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161214 |
|
| WD01 | Invention patent application deemed withdrawn after publication |